Crossref
Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?
JAMA · 10.11.2026 · 336 (18) · 1587
DOI: 10.1001/jama.2026.20002 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 10.11.2026. Verfasst von Jennifer Abbasi. Beteiligte Einrichtung: Director, Medical News, JAMA. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
This Medical News article discusses the top-line results from the Lp(a)HORIZON trial, which investigated lipoprotein(a) lowering to reduce major adverse cardiovascular events.
Autor:innen und Institutionen
- Director, Medical News, JAMA.
Zitieren
APA
Abbasi, J. (2026). Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?. JAMA, 336(18), 1587. https://doi.org/10.1001/jama.2026.20002
Vancouver
Abbasi J. Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?. JAMA. 2026;336(18):1587. doi:10.1001/jama.2026.20002
BibTeX
@article{Abbasi2026,
author = {Abbasi, Jennifer},
title = {Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?},
journal = {JAMA},
year = {2026},
volume = {336},
number = {18},
pages = {1587},
doi = {10.1001/jama.2026.20002}
}
EUVIMED